and 2015. Prescription claims were examined for statin, ACEi/ARB, and AP medications. Linear regression analysis was performed to assess for trends. Results: During the study interval, we identified 237,324 patients… Click to show full abstract
and 2015. Prescription claims were examined for statin, ACEi/ARB, and AP medications. Linear regression analysis was performed to assess for trends. Results: During the study interval, we identified 237,324 patients (49% female) with a diagnosis of PAD with a mean age of 67.6 (12.4) years. The proportion of women increased from 47% to 50% of patients over the study interval (test for trend, P < .01). Overall, 73.2% patients had IC and 26.8% had a diagnosis of CLI. Patients were predominantly white and lived in the South. Over the study interval, 22.2%% of patients were on an AP agent, and 50.8% were on a statin. AP rates decreased 26% to 19% over the study interval; however, statin use increased from 50% to 54%. The rate of statin + ACEi/ARB use was 36.2% and also increased slightly from 33% to 37%. Use of AP + statin + ACEi/ARB was stable at 11.8% (11% to 13%, Fig). Conclusions: Although statin use has increased, overall patients within PAD remain undertreated for their cardiovascular disease with potentially only 12% receiving optimal medical therapy of statin, ACEi/ARB and antiplatelet medications. These patients remain at increased risk for cardiovascular events and administrative data may be used to identify these patients at high risk of under-treatment for future targeted interventions.
               
Click one of the above tabs to view related content.